91,195 results match your criteria Arthritis research & therapy[Journal]


'Acute Flare-Ups' In Patients With, Or At High Risk Of, Knee Osteoarthritis: A Daily Diary Study With Case-Crossover Analysis.

Osteoarthritis Cartilage 2019 Apr 14. Epub 2019 Apr 14.

Clinical Epidemiology, Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences, Keele University, UK. Electronic address:

Objective: To determine the natural history of flare-ups in knee osteoarthritis and their relation to physical exposures.

Design: Adults aged ≥45 years with a recent primary care consultation for knee OA/arthralgia completed a daily pen-and-paper diary for up to 3 months, including questions on average knee pain intensity, pain descriptors, other symptoms, activity interference, and selected physical exposures (prolonged kneeling, squatting, climbing stairs, ladders, and moving/lifting heavy objects). Informed by a systematic review, flare-ups were defined a priori. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.joca.2019.04.003DOI Listing

Targeting Interleukin-6 Signaling in Clinic.

Immunity 2019 Apr;50(4):1007-1023

Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita City, Osaka, Japan. Electronic address:

Interleukin-6 (IL-6) is a pleiotropic cytokine with roles in immunity, tissue regeneration, and metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue injury, but excessive synthesis of IL-6 and dysregulation of IL-6 receptor signaling is involved in disease pathology. Therapeutic agents targeting the IL-6 axis are effective in rheumatoid arthritis, and applications are being extended to other settings of acute and chronic inflammation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10747613193014
Publisher Site
http://dx.doi.org/10.1016/j.immuni.2019.03.026DOI Listing
April 2019
1 Read

Combined Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation to Model Inflammatory Lung Disease in Rheumatoid Arthritis.

J Bone Miner Res 2019 Apr 17. Epub 2019 Apr 17.

Veterans Affairs Nebraska-Western Iowa Health Care System, Research Service, Omaha, NE.

Objectives: Rheumatoid Arthritis (RA) is characterized by extra-articular involvement including lung disease, yet the mechanisms linking the two conditions are poorly understood. The collagen-induced arthritis (CIA) model was combined with the organic dust extract (ODE) airway inflammatory model to assess bone/joint-lung inflammatory outcomes.

Methods: DBA/1J mice were intranasally treated with saline or ODE daily for 5 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.3745DOI Listing

Silicon intake and plasma level and their relationships with systemic redox and inflammatory markers in rheumatoid arthritis patients.

Adv Clin Exp Med 2019 Apr 15. Epub 2019 Apr 15.

Department of Food Science and Dietetics, Wroclaw Medical University, Poland.

Background: The nutritional significance of silicon for the human body is highlighted by a continually growing body of evidence. In conditions of excessive reactive oxygen species and upregulated immune response, silicon has been observed to provide benefits, but its role in redox and inflammatory status has not yet been examined in rheumatoid arthritis (RA).

Objectives: The aim of this study was to assess the relationship of silicon intake and plasma level to systemic indices of redox status and inflammation in patients with RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17219/acem/105380DOI Listing

Care quality for rheumatoid arthritis patients in Quebec.

Int J Rheum Dis 2019 Apr 16. Epub 2019 Apr 16.

Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.

Aim: The aims of this study were to: (a) measure the proportion of CARTaGENE rheumatoid arthritis (RA) patients fulfilling pre-specified quality indicators (ie disease-modifying antirheumatic drug [DMARD] use, regular follow up, use of folate supplementation, use of vitamin D and calcium, exercise and smoking status); and (b) examine variation in DMARD use with respect to patient age, sex, education and income.

Methods: A cohort of RA patients was constructed based on the CARTaGENE survey and health administrative database. CARTaGENE is a large, established, population-based study which recruited 19 995 participants from four metropolitan regions in Quebec. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13580DOI Listing

Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals.

Commun Biol 2019 8;2:115. Epub 2019 Apr 8.

5Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, 359-8513 Japan.

Gout is a common arthritis caused by elevated serum uric acid (SUA) levels. Here we investigated loci influencing SUA in a genome-wide meta-analysis with 121,745 Japanese subjects. We identified 8948 variants at 36 genomic loci (<5 × 10) including eight novel loci. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s42003-019-0339-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453927PMC

The assessment of instability in the osteoarthritic knee.

EFORT Open Rev 2019 Mar 8;4(3):70-76. Epub 2019 Mar 8.

Department of Biomedical Engineering, University of Strathclyde, Glasgow, UK.

Patient-reported instability is a common complaint amongst those with knee arthritis.Much research has examined the assessment of self-reported instability in the knee; however, no definitive quantitative measure of instability has been developed.This review focuses on the current literature investigating the nature of self-reported instability in the arthritic knee and discusses the possibilities of further investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1302/2058-5241.4.170079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440299PMC

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.

Dig Liver Dis 2019 Apr 13. Epub 2019 Apr 13.

IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address:

Background: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis.

Aims: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription.

Methods: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2019.03.007DOI Listing

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.

J Clin Med 2019 Apr 15;8(4). Epub 2019 Apr 15.

Division of Rheumatology, Medical University Department, Kantonsspital Aarau, 5001 Aarau, Switzerland.

Methotrexate (MTX) is a remarkable drug with a key role in the management of rheumatoid arthritis (RA) at every stage of its evolution. Its attributes include good overall efficacy for signs and symptoms, inhibition of structural damage and preservation of function with acceptable and manageable safety, a large dose-titratable range, options for either an oral or parenteral route of administration, and currently unrivalled cost-effectiveness. It has a place as a monotherapy and also as an anchor drug that can be safely used in combination with other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or used concomitantly with biological DMARDs or targeted synthetic DMARDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8040515DOI Listing

Translational drug discovery and development with the use of tissue-relevant biomarkers: towards more physiological relevance and better prediction of clinical efficacy.

Exp Dermatol 2019 Apr 16. Epub 2019 Apr 16.

Sanofi, Global Head of Immunology Therapeutic Research Area, 640 Memorial Drive, Cambridge, MA, 02139, USA.

Due to the clinical development of drugs such as secukinumab, ustekinumab and dupilumab, major changes have been achieved in the treatment of patients diagnosed with psoriasis and atopic dermatitis. In academia and the pharmaceutical industry, research is increasingly moving towards the development of bi-specific antibodies and multi-specific nanobodies, as there is a compelling need for new treatment modalities for patients suffering from auto-immune or malignant disease. The purpose of this review is to discuss aspects of translational drug development with a particular emphasis on indications such as psoriasis and atopic dermatitis. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.13942
Publisher Site
http://dx.doi.org/10.1111/exd.13942DOI Listing
April 2019
2 Reads

Type of job, personal factors, and disease status are important contextual factors when measuring worker productivity in people with arthritis: a Delphi study.

Disabil Rehabil 2019 Apr 16:1-8. Epub 2019 Apr 16.

a Department of Rehabilitation and Movement Science , University of Vermont , Burlington , VT , USA.

Purpose: Arthritis is associated with lost wages, work disability, and decreased productivity. There is a lack of knowledge regarding contextual factors that influence worker productivity to inform rehabilitation. Our study aims to identify the essential contextual factors that need to be considered when measuring worker productivity outcomes in people with arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09638288.2019.1597181DOI Listing

[Effect of ethanolic extract of Polygonum cuspidatum on acute gouty arthritis in mice through NLRP3/ASC/caspase-1 axis].

Zhongguo Zhong Yao Za Zhi 2019 Feb;44(3):546-552

College of Pharmaceutical Sciences, Zhejiang Chinese Medical University Hangzhou 310053, China.

The aim of this paper was to study the effect and mechanism of alcohol extract from Polygonum cuspidatum(PCE) on acute gouty arthritis in C57 BL/6 mice through NLRP3/ASC/caspase-1 axis. The model mice which injected with ankle joint injection of sodium urate crystals(MSU) were orally administrated with three different concentration of PCE, with colchicine as positive control. HE staining was used for observing the morphological changes of synovial tissue; concentration of IL-1β, IL-6 and TNF-α secreted by synovial tissue of the ankle joint were detected by ELISA; mRNA and protein expression of NLRP3, ASC and caspase-1 in synovial tissue were detected by RT-PCR and Western blot respectively. Read More

View Article

Download full-text PDF

Source
http://www.cnki.net/kcms/doi/10.19540/j.cnki.cjcmm.20180925.
Publisher Site
http://dx.doi.org/10.19540/j.cnki.cjcmm.20180925.001DOI Listing
February 2019
1 Read

[Research progress of studies on chemical constituents and biologic activities of Anemone species].

Zhongguo Zhong Yao Za Zhi 2019 Mar;44(5):912-919

Key Laboratory of Bological Resources Protection and Utilization of Hubei Province Enshi 445000,China.

Anemone is an important genus which was distributed widely and used to folk medicines in China. It is rich of pentacyclic triterpenoid saponins,and more than 100 kinds of pentacyclic triterpenoid saponins had been isolated and identified. Anemone has been used to treat punch injury and rheumatoid arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20181226.011DOI Listing

Upper extremity myxofibrosarcoma mimicking an erosive inflammatory arthritis: a case report.

Skeletal Radiol 2019 Apr 15. Epub 2019 Apr 15.

Imaging Institute, Cleveland Clinic, 9500 Euclid Ave. A21, Cleveland, OH, 44195, USA.

Myxofibrosarcoma is a malignant fibroblastic soft tissue neoplasm containing a variable amount of myxoid stroma that commonly presents as a slow-growing mass in elderly patients. The neoplasm may be superficial or deep to the muscle fascia and characteristically has an infiltrative growth pattern with a dominant or multinodular mass. We describe an unusual case of high-grade myxofibrosarcoma of the wrist and forearm that infiltrated the muscles, tendons, and wrist joint, causing bone erosions. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00256-019-03217-w
Publisher Site
http://dx.doi.org/10.1007/s00256-019-03217-wDOI Listing
April 2019
1 Read

Serological Diagnosis of Lentivirus Infection in Goats Raised in Algeria.

J Vet Res 2019 Mar 22;63(1):27-33. Epub 2019 Mar 22.

INRA/UGA USC 1450, Pathogenesis and Lentivirus Vaccination Laboratory, PAVAL Lab., Université Grenoble Alpes, 38041, Grenoble Cedex 9, France.

Introduction: Infection of goats with caprine arthritis encephalitis virus (CAEV) has been detected in variable proportions in many countries all over the world. Here, we investigated the seroprevalence of CAEV in goats raised in Algeria.

Material And Methods: A serological survey was performed on serum samples from 1,313 goats, including the local breeds (Arabia and Dwarf of Kabylia) and imported European breeds (Alpine and Saanen). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/jvetres-2019-0001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458564PMC

Aspects of exercise with person-centred guidance influencing the transition to independent exercise: a qualitative interview study among older adults with rheumatoid arthritis.

Eur Rev Aging Phys Act 2019 5;16. Epub 2019 Apr 5.

1Department of Health and Rehabilitation, Unit of Physiotherapy, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Box 455, 405 30 Göteborg, Gothenburg, Sweden.

Background: Besides being health enhancing and disease preventing, exercise is also an important part of the management of chronic conditions, including the inflammatory joint disease rheumatoid arthritis (RA). However, older adults with RA present a lower level of physical activity than healthy older adults. The aim of this qualitative study was to explore aspects of participation in moderate- to high-intensity exercise with person-centred guidance influencing the transition to independent exercise for older adults with RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s11556-019-0211-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449916PMC

Inhibitory effect of tanshinone IIA on inflammatory response in rheumatoid arthritis through regulating β-arrestin 2.

Exp Ther Med 2019 May 12;17(5):3299-3306. Epub 2019 Mar 12.

Department of Emergency, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China.

The current study aimed to investigate the inhibitory effect of tanshinone IIA (Tan IIA) on the inflammatory response in patients with rheumatoid arthritis (RA) and explore its mechanism. A total of 50 patients with RA were randomly separated into the control group (15 cases) and the research group (35 cases). The tumor necrosis factor (TNF)-α and interleukin (IL)-6 levels in serum were determined, and peripheral blood mononuclear cells (PBMCs) were separated from patients with RA and cultured . Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/etm.2019.7371
Publisher Site
http://dx.doi.org/10.3892/etm.2019.7371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447808PMC
May 2019
1 Read

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

Department of Medicine, Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Community Health & Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada; Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea;Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico; Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA; Division of Rheumatology, CHU de Québec et Université Laval, Quebec City, Canada; Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, ON, Canada; Arthritis Research UK Epidemiology Unit, Faculty of Biology Medicine and Health, Manchester Academic Health Sciences Center, The University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Center Manchester, UK; Center for Rheumatology, Department of Medicine, University College London, UK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, UK, London, UK; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA; Northwestern University and Feinberg School of Medicine, Chicago, IL, USA; Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA, USA; Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland UK; Feinstein Institute for Medical Research, Manhasset, NY, USA; Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain; Emory University School of Medicine, Division of Rheumatology, Atlanta, Georgia, USA Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey; Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden; Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden. Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain; Medical University of South Carolina, Charleston, South Carolina, USA; UCSD School of Medicine, La Jolla, CA, USA; Copenhagen Lupus and Vasculitis Clinic, 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; University of Manitoba, Winnipeg, Manitoba, Canada; Hospital for Joint Diseases, NYU, Seligman Center for Advanced Therapeutics, New York NY; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada. Funding for this work was provided by the Nova Scotia Health Authority Research Fund. Dr. Sang-Cheol Bae's work was supported in part by NRF-2017M3A9B4050335, Republic of Korea. Dr. Caroline Gordon's work was supported by Lupus UK and the NIHR /Wellcome Trust Clinical Research Facility. The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Université Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is supported by Arthritis Research UK, the NIHR Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Dr Isenberg and Dr Rahman are supported by and supported by the National Institute for Health, Research University College London Hospitals Biomedical Research Center. The Hopkins Lupus Cohort is supported by the NIH (grant AR43727 and 69572). Dr. Mary Anne Dooley's work was supported by the NIH (grant RR00046). Dr. Ramsey-Goldman's work was supported by the NIH (grants 5UL1TR001422-02, formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464 formerly P60-AR- 48098). Dr. Ruiz-Irastorza is supported by the Department of Education, Universities and Research of the Basque Government. Dr. Soren Jacobsen is supported by the Danish Rheumatism Association (A3865) and the Novo Nordisk Foundation (A05990). Dr. John G. Hanly is supported by the Canadian Institutes of Health Research (grant MOP-88526). Address Correspondence to: Dr. John G Hanly, Division of Rheumatology, Nova Scotia Rehabilitation Centre (2nd Floor), 1341 Summer Street, Halifax, Nova Scotia, Canada, B3H 4K4.Email:

Objective: To construct a frailty index (FI) as a measure of vulnerability to adverse outcomes among patients with SLE, using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Methods: The SLICC inception cohort consists of recently diagnosed SLE patients followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study visit at which sufficient information was available for construction of a frailty index. Read More

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.181338
Publisher Site
http://dx.doi.org/10.3899/jrheum.181338DOI Listing
April 2019
1 Read

Anti-CCP3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

From the Division of Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA; Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, USA; Division of Rheumatology, Veteran Affairs Nebraska Western Iowa Health Care System, Omaha, NE, USA; Department of Research, INOVA Diagnostics, San Diego, CA, USA; Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Division of Rheumatology, Scripps Green Hospital, La Jolla, CA, USA; Department of Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA; Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, USA. This work was supported by the National Institutes of Health [grant numbers AR066712, AI110503, AI101981, and T32AR007534], and a Rheumatology Research Foundation Resident Research Preceptorship Award. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. Address correspondence to M. Kristen Demoruelle, MD, PhD University of Colorado Denver School of Medicine Division of Rheumatology 1775 Aurora Court, Mail Stop B-115 Aurora, CO 80045 Email:

Objective: We investigated the association of age and anti-cyclic citrullinated peptide (CCP) antibodies in subjects without RA.

Methods: Serum was tested for anti-CCP3.1 (IgG/IgA) in 678 first-degree relatives (FDRs) of RA patients and 330 osteoarthritis (OA) subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180897DOI Listing

Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

From the Department of Medicine and Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; Arthritis Research Canada; Centre for Health Evaluation and Outcome Sciences, Providence Health Care, St Paul's Hospital, Vancouver, British Columbia. The work was supported in part by a Canadian Initiative for Outcomes in Rheumatology Care (CIORA) grant. Dr. Hazlewood is supported by a Canadian Institute of Health Research (CIHR) New Investigator Salary Award and The Arthritis Society Young Investigator Salary Award. Dr. Marshall is supported by a CIHR Canada Research Chair in Health Services and Systems Resea. Address correspondence to Dr. Glen Hazlewood, 3330 Hospital Dr NW, Calgary, Alberta, Canada, T2N 4N1 Tel: (403) 220-5903, Fax: (403) 210-7367 Email:

Objective: To summarize patients' preferences for disease modifying anti-rheumatic drug (DMARD) therapy in rheumatoid arthritis (RA).

Methods: We conducted a systematic review to identify English-language studies in adult RA patients that measured patients' preferences for DMARDs or health states and treatment outcomes relevant to DMARD decisions. Study quality was assessed using a published quality assessment tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181165DOI Listing

Precision, Reliability and Responsiveness of a Novel Automated Quantification Tool for Cartilage Thickness: Data from the Osteoarthritis Initiative.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

Imorphics Ltd, Manchester, UK; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK. Scientific and financial support for the FNIH OA Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie; Amgen; Arthritis Foundation; Bioiberica S.A; DePuy Mitek; Flexion Therapeutics; GlaxoSmithKline; Merck Serono; Rottapharm Madaus; Sanofi; and Stryker; The Pivotal OAI MRI Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public-private partnership comprised of five contracts (N01-AR-2- 2258;N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health. Funding partners include Merck Research Laboratories;Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer. Private sector funding for the Consortium and OAI is managed by the FNIH. PGC has undertaken consultancies or speakers bureaus for Abbvie, Flexion, Galapagos, GSK, Medivir, Novartis, Pfizer, Samumed, Servier, TissueGene, MAB, GG, GRV, CBW, AB are employees of Imorphics Ltd, a wholly owned subsidiary of Stryker Corp. Address correspondence to Philip G Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Rd, Leeds LS7 4SA, UK. Email:

Objective: Accurate automated segmentation of cartilage should provide rapid reliable outcomes for both epidemiological studies and clinical trials. We aimed to assess the precision and responsiveness of cartilage thickness measured with careful manual segmentation or a novel automated technique.

Methods: Agreement of automated segmentation was assessed against two manual segmentation datasets: 379 MR images manually segmented in-house (Training set), and 582 from the OAI with data available at 0, 1, and 2 years (Biomarkers set). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180541DOI Listing

Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

From McMaster University, Hamilton, Ontario; Southlake Regional Health Centre, Newmarket, Ontario; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario; JSS Medical Research; McGill University, Montreal, Quebec; University of Toronto, Department of Medicine and Institute of Health Policy, Management, and Evaluation; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. OBRI was funded by peer-reviewed grants from Canadian Institute for Health Research (CIHR), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN), and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. MM, AC, XL, SC, and CB are employees at OBRI, which was funded by peer-reviewed grants from CIHR, MOHLTC, CAN, and unrestricted grants from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi, and UCB. ER and JSS are employees at JSS Medical Research, a contract research organization. A.N. Lau, MD, McMaster University; J.C. Thorne, MD, Southlake Regional Health Centre; M. Movahedi, MD, PhD, Toronto General Hospital Research Institute, University Health Network; E. Rampakakis, PhD, JSS Medical Research; A. Cesta, BSc, Toronto General Hospital Research Institute, University Health Network; X. Li, BSc, Toronto General Hospital Research Institute, University Health Network; S. Couto, MSc, Toronto General Hospital Research Institute, University Health Network; J. Sampalis, PhD, JSS Medical Research, and McGill University; C. Bombardier, MD, Toronto General Hospital Research Institute, University Health Network, and University of Toronto, Department of Medicine and Institute of Health Policy, Management, and Evaluation, and Mount Sinai Hospital, Division of Rheumatology. Address correspondence to Dr. A.N. Lau, 501-25 Charlton Ave. East, Hamilton, Ontario L8N 1Y2, Canada. E-mail: Accepted for publication October 30, 2018.

Objective: Prior studies have suggested that concurrent conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy enhances the efficacy of biologic DMARD (bDMARD). Here, we assessed the effect of concomitant csDMARD use and methotrexate (MTX) route of administration on time to bDMARD discontinuation in a large Canadian (Ontario), observational, rheumatoid arthritis (RA) cohort.

Methods: Patients from the Ontario Best Practices Research Initiative (OBRI) who initiated bDMARD therapy and had ≥ 1 followup assessment were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180486DOI Listing

Report on the 2018 Cancer, Autoimmunity, and Immunology Conference.

J Immunol 2019 Apr 15. Epub 2019 Apr 15.

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

With the increased use of cancer immunotherapy, a number of immune-related adverse events (irAEs) are being identified. These irAEs can be compared with known autoimmune disorders in similar tissues, with important similarities and differences. Understanding the etiology of irAEs may bring to light concepts applicable to immune responses in cancer, autoimmunity, and infectious disease. Read More

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1900264
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1900264DOI Listing
April 2019
1 Read

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

J Immunol 2019 Apr 15. Epub 2019 Apr 15.

Translational Innovation Platform Immunology, EMD Serono Research and Development Institute, Billerica, MA 01821; and

Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptormediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils. We evaluated evobrutinib in preclinical models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1800583DOI Listing

Is Palindromic Rheumatism a Pre-rheumatoid Arthritis Condition? Low Incidence of Rheumatoid Arthritis in Palindromic Rheumatism Patients Treated with Tight Control Strategy.

Reumatol Clin 2019 Apr 13. Epub 2019 Apr 13.

Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:

Objectives: Palindromic rheumatism (PR) is characterized by repetitive, afebrile episodes of acute arthritis and peri-arthritis. The aim of this study was considering the long-term outcomes of patients with PR who were treated with tight control strategy using Disease-modifying anti-rheumatic drugs (DMARDs).

Methods: We reviewed the charts of 106 patients diagnosed with PR who were referred to the Connective Tissue Diseases Research Center (CTDRC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reuma.2019.01.002DOI Listing

Low back pain precedes the development of new knee pain in the elderly population; a novel predictive score from a longitudinal cohort study.

Arthritis Res Ther 2019 Apr 15;21(1):98. Epub 2019 Apr 15.

Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo, Kyoto, 606-8507, Japan.

Background: To investigate the association between knee pain and risk factors including low back pain and to develop a score to predict new knee pain in an older population, using population-based longitudinal cohort data.

Methods: We collected a questionnaire on self-reported knee pain and demographic data in a systematic manner from community residents aged ≥ 50 years twice, at baseline, and after 5 years. Multivariate logistic regression analyses were performed to investigate the association between knee pain and risk factors and to build a predictive model that would enable calculation of the risk of the development of knee pain within 5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1884-0DOI Listing

Research of Pathogenesis and Novel Therapeutics in Arthritis.

Authors:
Chih-Hsin Tang

Int J Mol Sci 2019 Apr 2;20(7). Epub 2019 Apr 2.

Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan.

Arthritis has a high prevalence globally and includes over 100 types, the most common of which are rheumatoid arthritis, osteoarthritis, psoriatic arthritis and inflammatory arthritis. The exact etiology of arthritis remains unclear and no cure exists. Anti-inflammatory drugs are commonly used in the treatment of arthritis, but are associated with significant side effects. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/1422-0067/20/7/1646
Publisher Site
http://dx.doi.org/10.3390/ijms20071646DOI Listing
April 2019
1 Read

Assessing Radiographic Knee Osteoarthritis: An Online Training Tutorial for the Kellgren-Lawrence Grading Scale.

MedEdPORTAL 2016 Nov 18;12:10503. Epub 2016 Nov 18.

Professor, Physical Therapy Department, University of Colorado School of Medicine Anschutz Medical Campus.

Introduction: Knee osteoarthritis (OA) is a degenerative form of arthritis commonly diagnosed in older adults. It presents clinically with patient complaints of pain and impaired function, which are thought to result from cartilage degeneration and other skeletal changes. These changes can by examined radiographically and quantified using the semiquantitative grading scale known as the Kellgren-Lawrence (KL) scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15766/mep_2374-8265.10503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440422PMC
November 2016

Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada.

Front Med (Lausanne) 2019 28;6:58. Epub 2019 Mar 28.

Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada.

Canadian academic and industry stakeholders are concerned about the inclusion of "virus-like particles or sub-viral particles" in the definition of which impacts clinical cell and gene therapy and commercialization. The requirement of an independent 120 days Environment and Climate Change Canada (ECCC) review preceding a Health Canada review on quality environmental concerns places an additional burden on Sponsors submitting clinical trial applications (CTA) and/or New Drug Submissions (NDS). A workshop initiated by CellCAN and BIOTECanada with participants from Environment and Climate Change Canada, Health Canada, the Public Health Agency of Canada and Innovation, Science and Economic Development (Ottawa, March 19, 2018) with invited stakeholders discussed approaches to streamline the environmental review process. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fmed.2019.00058/
Publisher Site
http://dx.doi.org/10.3389/fmed.2019.00058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447701PMC
March 2019
1 Read

Effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis.

J Family Med Prim Care 2019 Feb;8(2):517-522

Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.

Background: To assess effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis (RA).

Materials And Methods: An open-labeled randomized trial was conducted comparing 60,000 IU 1,25 dihydroxy vitamin D3 + calcium (1000 mg/day) combination [Group A] versus calcium (1000 mg/day) only [Group B], as supplement to existing treatment regimen in early RA. Primary outcome included (i) minimum time required for onset of pain relief (Tm) assessed through patients' visual analog scale (VAS); (ii) % change in VAS score from onset of pain relief to end of 8 weeks. Read More

View Article

Download full-text PDF

Source
http://www.jfmpc.com/text.asp?2019/8/2/517/253057
Publisher Site
http://dx.doi.org/10.4103/jfmpc.jfmpc_446_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436291PMC
February 2019
1 Read

CD28 CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection.

F1000Res 2019 25;8. Epub 2019 Mar 25.

Department of Clinical and Experimental medicine, Brighton and Sussex Medical School, Brighton, Sussex, BN1 9PX, UK.

Immunosenescence is thought to contribute to the increase of autoimmune diseases in older people. Immunosenescence is often associated with the presence of an expanded population of CD4 T cells lacking expression of CD28 (CD28 ). These highly cytotoxic CD4 T cells were isolated from disease-affected tissues in patients with rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, or other chronic inflammatory diseases and their numbers appeared to be linked to disease severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.17119.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436193PMC

The RANKL-RANK Axis: A Bone to Thymus Round Trip.

Front Immunol 2019 29;10:629. Epub 2019 Mar 29.

Milan Unit, Institute for Genetic and Biomedical Research (CNR-IRGB), Milan, Italy.

The identification of Receptor activator of nuclear factor kappa B ligand (RANKL) and its cognate receptor Receptor activator of nuclear factor kappa B (RANK) during a search for novel tumor necrosis factor receptor (TNFR) superfamily members has dramatically changed the scenario of bone biology by providing the functional and biochemical proof that RANKL signaling via RANK is the master factor for osteoclastogenesis. In parallel, two independent studies reported the identification of mouse RANKL on activated T cells and of a ligand for osteoprotegerin on a murine bone marrow-derived stromal cell line. After these seminal findings, accumulating data indicated RANKL and RANK not only as essential players for the development and activation of osteoclasts, but also for the correct differentiation of medullary thymic epithelial cells (mTECs) that act as mediators of the central tolerance process by which self-reactive T cells are eliminated while regulatory T cells are generated. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00629
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450200PMC
March 2019
1 Read

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Front Pharmacol 2019 28;10:279. Epub 2019 Mar 28.

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Biological therapies are an effective treatment for a range of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. However, due to their high costs, considerable differences in their utilization exist across the world, even among the various European countries, with many countries restricting access despite professional society guideline recommendations. Adoption of biologics by healthcare providers has been particularly poor in many Central and Eastern European countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447826PMC

Sox9+ messenger cells orchestrate large-scale skeletal regeneration in the mammalian rib.

Elife 2019 Apr 15;8. Epub 2019 Apr 15.

Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Keck School of Medicine, Los Angeles, United States.

Most bones in mammals display a limited capacity for natural large-scale repair. The ribs are a notable exception, yet the source of their remarkable regenerative ability remains unknown. Here, we identify a -expressing periosteal subpopulation that orchestrates large-scale regeneration of murine rib bones. Read More

View Article

Download full-text PDF

Source
https://elifesciences.org/articles/40715
Publisher Site
http://dx.doi.org/10.7554/eLife.40715DOI Listing
April 2019
1 Read

Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing 400042, PR China.

Aim: This study was conducted to investigate the relationship between ABCB1 gene C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients.

Methods: Seven electronic databases (PubMed, EMBASE, Web of Science, Cochrane, OVID, Chinese biomedical literature [CBM], China National Knowledge Infrastructure [CNKI] and Wanfang databases) were searched to select eligible publications until 18 July 2018. The references of relevant articles were also manually searched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0172DOI Listing

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial.

Arthritis Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester.

Objective: Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVE in RA patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40892DOI Listing

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rheumatology (Oxford) 2019 Apr 14. Epub 2019 Apr 14.

Department of Inflammation Biology, School of Immunology & Microbial Sciences.

Objective: To evaluate whether polypharmacy is associated with treatment response and serious adverse events (SAEs) in patients with RA using data from the British Society for Rheumatology Biologics Register (BSRBR-RA).

Methods: The BSRBR-RA is a prospective observational cohort study of biologic therapy starters and a DMARD comparator arm. A logistic regression model was used to calculate the odds of a EULAR 'good response' after 12 months of biologic therapy by medication count. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez037DOI Listing

A Case of Knee Monoarthritis Caused by Mycobacterium Tuberculosis.

Am J Case Rep 2019 Apr 15;20:522-524. Epub 2019 Apr 15.

Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.

BACKGROUND Skeletal involvement is an uncommon form of extrapulmonary Mycobacterium tuberculosis (MTB) that occurs in 1-3% of the patients. Knee joints may be affected in 8% of cases. CASE REPORT We reported a case of TB knee arthritis in a 35-year-old Afghan male who was referred to Kashan Rheumatology Clinic for pain and swelling in the left knee. Read More

View Article

Download full-text PDF

Source
https://www.amjcaserep.com/abstract/index/idArt/915150
Publisher Site
http://dx.doi.org/10.12659/AJCR.915150DOI Listing
April 2019
1 Read

The CNS theory of osteoarthritis: Opportunities beyond the joint.

Semin Arthritis Rheum 2019 Mar 16. Epub 2019 Mar 16.

The Orthopaedic Research Institute of Queensland (ORIQL), Townsville 4812, Queensland, Australia; Heart, Trauma and Sepsis Research Laboratory, College of Medicine and Dentistry, James Cook University, 1 James Cook Drive, 4811, Queensland, Australia. Electronic address:

Osteoarthritis (OA) is a leading cause of global disability that affects more than half of the population over 65. It is not a single disease but a progressive, inflammatory- and immune-altering multi-disease that affects the whole joint. OA has many risk factors including age, obesity, gender, lifestyle, joint morphology, metabolic dysfunction and genetic disposition. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00490172193001
Publisher Site
http://dx.doi.org/10.1016/j.semarthrit.2019.03.008DOI Listing
March 2019
2 Reads

Tofacitinib in the treatment of moderate to severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.

J Med Econ 2019 Apr 13. Epub 2019 Apr 13.

h Pfizer Inc , Groton , CT , USA.

Aims: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis investigated the cost-effectiveness of the second-line treatment with tofacitinib, compared with adalimumab, both plus methotrexate (MTX), in patients with moderate to severe RA and an inadequate response to the first-line MTX, from a Taiwan National Health Insurance Administration perspective.

Materials And Methods: A patient-level simulation model was used to project lifetime costs and quality-adjusted life-years (QALYs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1606813DOI Listing

Therapeutic advances in arthritis diseases.

Biochem Pharmacol 2019 Apr 11. Epub 2019 Apr 11.

Laboratory of Rheumatology, GIGA Research, University and CHU of Liège, 4000 Liège, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2019.04.014DOI Listing

Imaging calcinosis in patients with systemic sclerosis by radiography, computerised tomography and magnetic resonance imaging.

Semin Arthritis Rheum 2019 Mar 9. Epub 2019 Mar 9.

Centre for Musculoskeletal Research, The University of Manchester, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, UK.

Introduction: Objective outcome measures are needed to facilitate clinical trials of much needed treatments for calcinosis in systemic sclerosis (SSc). Our primary aim was to compare radiography, computed tomography (CT) and magnetic resonance imaging (MRI) to measure calcinotic lesions. Secondary objectives included to examine reproducibility of radiography and MRI, and inter-rater reliability of MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.03.001DOI Listing

Ethanol extract of Polyscias fruticosa leaves suppresses RANKL-mediated osteoclastogenesis in vitro and LPS-induced bone loss in vivo.

Phytomedicine 2019 Apr 2;59:152908. Epub 2019 Apr 2.

Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon, Gangwon-Do 24341, Republic of Korea. Electronic address:

Background: Many bone-related diseases such as osteoporosis and rheumatoid arthritis are commonly associated with the excessive activity of osteoclasts. Polyscias fruticosa has been used as traditional medicine for the treatment of ischemia and inflammation and also eaten as a salad. However, its effect on the bone related diseases has not been investigated yet. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09447113193007
Publisher Site
http://dx.doi.org/10.1016/j.phymed.2019.152908DOI Listing
April 2019
2 Reads

Tibialis posterior muscle pain effects on hip, knee and ankle gait mechanics.

Hum Mov Sci 2019 Apr 10;66:98-108. Epub 2019 Apr 10.

Center for Sensory-Motoric Interaction (SMI®), Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7, DK-9220 Aalborg East, Denmark. Electronic address:

Background: Tibialis posterior (TP) dysfunction is a common painful complication in patients with rheumatoid arthritis (RA), which can lead to the collapse of the medial longitudinal arch. Different theories have been developed to explain the causality of tibialis posterior dysfunction. In all these theories, pain is a central factor, and yet, it is uncertain to what extent pain causes the observed biomechanical alterations in the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humov.2019.04.002DOI Listing

Alopecia areata is characterised by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity.

Br J Dermatol 2019 Apr 13. Epub 2019 Apr 13.

Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

Background: Alopecia areata (AA) is a common autoimmune disease, causing patchy hair loss that can progress to involve the entire scalp (totalis) or body (universalis). CD8 NKG2D T cells dominate hair follicle pathogenesis, but the specific mechanisms driving hair loss are not fully understood.

Objectives: To provide a detailed insight into the systemic cytokine signature associated with AA, and assess the association between cytokines and depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18008DOI Listing

TAM Receptors in Cardiovascular Disease.

Cardiovasc Res 2019 Apr 13. Epub 2019 Apr 13.

Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

The TAM receptors are a distinct family of three receptor tyrosine kinases, namely Tyro3, Axl and MerTK. Since their discovery in the early 1990s, they have been studied for their ability to influence numerous diseases, including cancer, chronic inflammatory and autoimmune disorders, and cardiovascular diseases. The TAM receptors demonstrate an ability to influence multiple aspects of cardiovascular pathology via their diverse effects on cells of both the vasculature and the immune system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvz100DOI Listing
April 2019
1 Read

Efficacy and Safety of Intravenous Golimumab through 1 Year in Patients with Active Psoriatic Arthritis.

Arthritis Care Res (Hoboken) 2019 Apr 12. Epub 2019 Apr 12.

Janssen Research & Development, LLC, Spring House, PA, USA.

Objective: Evaluate safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis (PsA) through 1 year.

Methods: GO-VIBRANT was a Phase 3, randomized, placebo-controlled trial of 480 adults with active PsA. Patients were randomized to intravenous placebo (n=239) or golimumab 2 mg/kg (n=241) at weeks 0, 4, 12, and 20, with placebo crossover to golimumab at weeks 24, 28, and q8w. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23905DOI Listing

A Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessments Measures in Rheumatoid Arthritis.

Arthritis Care Res (Hoboken) 2019 Apr 12. Epub 2019 Apr 12.

Department of Medicine & Department of Community Health Sciences, Cumming School of Medicine, University of Calgary; Arthritis Research Canada, Calgary, Alberta, Canada.

Objective: We conducted a systematic review and appraisal of the cross-cultural adaptation and cross-cultural validity of the Health Assessment Questionnaire (HAQ) and its derivatives, and the more recent Patient-Reported Outcomes Measurement Information System (PROMIS) Functional Status Assessment Measures (FSAMs) in rheumatoid arthritis (RA).

Methods: Four electronic medical databases were searched from inception until April 4 , 2018 according the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) group search strategy. Included studies were evaluated using the COSMIN tool for cross-cultural validity and were scored as excellent, good, fair or poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23904DOI Listing
April 2019
2 Reads

Comorbid interphalangeal joint pain and erosive osteoarthritis are associated with worse hand function in individuals with symptomatic thumb base OA.

Arthritis Care Res (Hoboken) 2019 Apr 12. Epub 2019 Apr 12.

Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, The University of Sydney, Sydney, New South Wales, Australia.

Objective: Hand osteoarthritis (OA) trials often target exclusively the thumb base joint although concomitant widespread interphalangeal (IP) involvement is frequent. We aimed to compare hand strength and function between individuals with isolated thumb base OA and those with co-existent IP joint pain and erosive OA.

Methods: Baseline data from a thumb base OA trial was analysed (n=204). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23902DOI Listing

Inhibition of the Prostaglandin EP-1 Receptor in Periosteum Progenitor Cells Enhances Osteoblast Differentiation and Fracture Repair.

Ann Biomed Eng 2019 Apr 12. Epub 2019 Apr 12.

Department of Orthopaedic Surgery, Washington University School of Medicine, 660 S. Euclid, CB 8233, St. Louis, MO, 63110, USA.

Fracture healing is a complex and integrated process that involves mesenchymal progenitor cell (MPC) recruitment, proliferation and differentiation that eventually results in bone regeneration. Prostaglandin E2 (PGE2) is an important regulator of bone metabolism and has an anabolic effect on fracture healing. Prior work from our laboratory showed EP1 mice have enhanced fracture healing, stronger cortical bones, higher trabecular bone volume and increased in vivo bone formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10439-019-02264-7DOI Listing